SEARCH · PubMed Health

Results for “PROST”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 739 records · Page 41Linked to original sources

PubMed2003

[Dapsone-induced sensory peripheral neuropathy].

INTRODUCTION: Peripheral neuropathy is a rare complication of dapsone therapy. CASE-REPORT: A 74 year-old woman was treated with dapsone, 50 mg per day, for a linear IgA dermatosis. One month later, the disease was controlled but the patient complained of a sensory peripheral neuropathy, which was documented on electromyographic studies. Dapsone was stopped and symptoms resolved within 24 hours. Three months after the beginning of linear IgA dermatosis, a colic adenocarcinoma was revealed by an acute occlusive syndrome. After surgical resection of the tumor, remission of linear IgA dermatosis was obtained with salazopyrine. DISCUSSION: This is a rare side effect of dapsone therapy. Twenty-one cases have been previously reported. In most cases, there was a pure motor or mixed neuropathy. Dapsone therapy was then stopped or decreased. Recovery usually occurs within one year after dapsone therapy is discontinued.

Aged↗

PubMed2003

[Possibilities of spontaneous regression in active phase of ROP].

PURPOSE: To evaluate the possibilities of spontaneous regression of changes in the retina and vitreous in active stage 1-5 retinopathy in prematurity. MATERIAL AND METHODS: 168 premature infants with active stages 1-3 and 91 with stages 4-5 ROP, was observed by the author in years 1995-2002. RESULTS: Spontaneous regression of changes in the retina and vitreous was observed in 85% of children with stage 1, in 56% in stage 2 and in 25% in stage 3. In stage 3 regression occurred in 35% in stage 3 A, in 18% in 3 B and in 12% in stage 3 C. With changes in zone III regression can be expected in 95%, in zone II in 45% and in zone I in 6%. Spontaneous reattachment of the retina was observed in 27% of children with stage 4A, in 15% with stage 4B and only in 6% in stage 5. CONCLUSIONS: Considering the occurrence of spontaneous regression, laser therapy should be performed in every stage, if changes are observed in zone I and in every case of stage 3 B and 3 C.

Child, Preschool↗

PubMed2003

Antioxidant status and levels of different vitamins determined by high performance liquid chromatography in diabetic subjects with multiple complications.

Plasma vitamin A, C and E levels and erythrocyte antioxidant enzyme activities were investigated in type I and type II diabetic subjects with and without complications, i.e., hypertension, coronary artery disease and renal failure. Reverse phase HPLC was used to quantify vitamin A and E levels. We observed that the vitamin C levels were not significantly different between control and diabetic subjects. However, vitamin A and E levels were significantly lower in type I and type II diabetic subjects compared to controls. Superoxide dismutase (SOD) activity was significantly lower in type II, but not in type I, diabetic patients compared to controls. Interestingly, glutathione reductase and peroxidase activities were diminished in type I, but not in type II, diabetic subjects as compared to controls. Catalase activity was lower in both types of diabetic patients in comparison with their respective controls. Altogether these results suggest that diabetes mellitus may be associated with altered antioxidant status regardless to various complications.

Adult↗

PubMed2003

Changes in serum lipids and antioxidant status in west Algerian patients with essential hypertension treated with acebutolol compared to healthy subjects.

BACKGROUND: Hypertension is a major health problem in both developed and developing countries. It is hypothesized that high blood pressure is associated with loss of balance between peroxidation and antioxidant factors. MATERIAL/METHODS: 40 patients with essential hypertension were studied to ascertain the effects of a selective b1-blocker (acebutolol, 400 mg/day) on serum lipids, antioxidant status, antioxidant enzyme activity in red blood cells (RBC), and membrane fatty acids composition. Each subject was screened by physical examination, ECG, echocardiography, and laboratory tests. The period of observation was 24 weeks, and the data were tested by 2-way ANOVA followed by Bartlett's least significant difference test. RESULTS: At 12 weeks, serum triacylglycerol was more elevated (+26%). At 24 weeks, apolipoprotein A-1 levels remained more elevated (+41%) in hypertensive subjects compared to controls. In hypertensive patients, total antioxidant status and total plasma antioxidant capability were lower at 12 weeks than controls, and increased after 24 weeks of treatment. At 12 weeks, superoxide dismutase, catalase and glutathione reductase activities in erythrocytes remained lower in hypertensive subjects compared to controls (-32%, -40% and -24%, respectively). At 24 weeks, these values were increased compared to those obtained at 12 weeks (+26%, +36% and +37%, respectively). At 12 and 24-weeks, total n-3 and n-6 fatty acids were decreased by 26%, 18% and 29%, 25%, respectively. CONCLUSIONS: These findings demonstrate the beneficial influence of a beta1-blocker (acebutolol) at 24 weeks by its action on serum lipids, antioxidant status and RBC antioxidant enzyme activities.

Acebutolol↗

PubMedDate not supplied